Get the Stockscreener App
14.15
14.85%
1.83
After Hours:
14.37
0.22
+1.55%
Lexaria Bioscience Corp stock is traded at $14.15, with a volume of 22,426.
It is up +14.85% in the last 24 hours and up +151.78% over the past month.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
See More
Previous Close:
$12.32
Open:
$12.26
24h Volume:
22,426
Relative Volume:
0.25
Market Cap:
$23.38M
Revenue:
$368.00K
Net Income/Loss:
$-9.54M
P/E Ratio:
-29.55
EPS:
-0.4788
Net Cash Flow:
$-9.47M
1W Performance:
+36.71%
1M Performance:
+151.78%
6M Performance:
+1,896%
1Y Performance:
+1,366%
1-Day Range:
$12.26
$14.37
1-Week Range:
$10.30
$14.37
52-Week Range:
$0.35
$14.37
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Name
Lexaria Bioscience Corp
Sector
Industry
Phone
250-765-6424
Address
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
14.15 | 18.62M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexaria Bioscience Corp Stock (LEXX) Latest News
Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - Kalkine
Lexaria to present at H.C. Wainwright Global Investment Conference in September 2026 - Pluang
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - New Castle News
A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan
Lexaria Bioscience Corp. (LEXX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs - The Globe and Mail
LEXX Looks 131.9% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience advances 12% on Australian tax rebate (LEXX:NASDAQ) - Seeking Alpha
Lexaria enters MTA with PegBio to test GLP-1 delivery tech - scanx.trade
LEXX Looks 129.0% Overvalued on GF Value™ - GuruFocus
Lexaria advances GLP-1 partnerships at BIO 2026 - scanx.trade
Lexaria Bioscience Receives Australian R&D Tax Incentive Credit - TipRanks
LEXX Looks 117.5% Overvalued on GF Value™ - GuruFocus
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com South Africa
Lexaria Bioscience receives AUD$3.67m Australian tax rebate - scanx.trade
Lexaria receives $2.6 million Australian R&D tax rebate - Investing.com
Lexaria nets $2.6M Australian tax rebate to fun... - Pluang
Lexaria Bioscience receives AUD 3.67M Australian R&D tax credit to fund clinical RD - TradingView
Lexaria Receives USD$2.6 Million Tax Rebate Payment - joplinglobe.com
Lexaria DehydraTECH 3.0 Boosts GLP-1 Drug Absorption in 2026 Study - TipRanks
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2 - Yahoo Finance
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Nigeria
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Lexaria Bioscience regains Nasdaq bid-price compliance, listing continued - TradingView
Delisting risk eases as Lexaria (NASDAQ: LEXX) regains bid-price compliance - Stock Titan
Lexaria Bioscience enters MTA with PegBio - TipRanks
LEXX Looks 64.3% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Signs PegBio Deal to Test DehydraTECH With GLP-1 Diabetes Drug - TipRanks
Lexaria Bioscience Corp. Enters Material Transfer Agreement with Pegbio Co., Ltd - marketscreener.com
Lexaria enters partnership with PegBio for GLP-1 drug delivery By Investing.com - Investing.com Australia
Lexaria enters partnership with PegBio for GLP-1 drug delivery - Investing.com
Lexaria Enters a Material Transfer Agreement With PegBio - Investing News Network
Lexaria Enters a Material Transfer Agreement with PegBio - TradingView
Lexaria and PegBio Plan Animal Studies on a GLP-1 Molecule - Stock Titan
Lexaria Bioscience Received Notice of Delisting - TradingView
Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Stock Price Forecast. Should You Buy LEXX? - StockInvest.us
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Stock News Today - TradingKey
Lexaria Bioscience Corp Authorizes 1-For-15 Reverse Stock SplitSEC Filing - TradingView
Lexaria Bioscience plans 1-for-15 reverse stock split By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp (LEXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexaria Bioscience Corp. Revenue Breakdown – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LEXX|Lexaria Bioscience Corp|Price:0.559|Chg%:-0.011 - TradingKey
Enterprise value to revenue forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Cash Flow - TradingKey
Lexaria Bioscience Corp Stock (LEXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):